本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙商证券股份有限公司（以下简称"浙商证券"或"公司"）第四届董事会 第三十七次会议于 2025 年 10 月 22 日以书面方式通知全体董事，于 10 月 28 日 发出补充通知，会议于 2025 年 10 月 30 日以通讯表决方式召开。会议应出席董 事 9 人，实际出席董事 9 人。会议的召开符合《公司法》和《公司章程》规定。 经审议，作出决议如下： 证券代码：601878 证券简称：浙商证券 公告编号：2025-062 浙商证券股份有限公司 第四届董事会第三十七次会议决议公告 一、审议通过《2025 年第三季度报告》 表决结果：9 票同意，0 票反对，0 票弃权。 本议案提交董事会前已经公司董事会审计委员会审议通过。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）上披露的《浙 商证券股份有限公司 2025 年第三季度报告》。 二、审议通过《关于公司会计政策变更的议案》 公司本次会计政策变更是根据财政部相关文件要求进行的合理变更，决策程 序符合有关 ...

Core Insights - Zhejiang Securities (601878.SH) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance [1] Financial Performance - The company achieved a revenue of 6.789 billion yuan, representing a year-on-year growth of 66.73% [1] - The net profit attributable to shareholders reached 1.892 billion yuan, with a year-on-year increase of 49.57% [1] - The non-recurring net profit was 1.867 billion yuan, showing a year-on-year growth of 49.75% [1] - Basic earnings per share stood at 0.42 yuan [1]

Core Insights - Zhejiang Securities (601878) reported a significant increase in revenue and net profit for Q3 2025, with operating income reaching 2.97 billion yuan, a year-on-year growth of 105.06% (adjusted) [1] - The net profit for Q3 2025 was 743 million yuan, reflecting a year-on-year increase of 54.61% (adjusted) [1] - For the first three quarters of 2025, the company achieved an operating income of 6.789 billion yuan, up 66.73% year-on-year (adjusted), and a net profit of 1.892 billion yuan, which is a 49.57% increase year-on-year (adjusted) [1] - The primary drivers for these performance changes were the increases in revenue from securities brokerage and proprietary trading businesses [1]

Core Insights - Zhejiang Securities (601878.SH) reported a significant increase in revenue and net profit for Q3 2025, with revenue reaching 2.97 billion yuan, a year-on-year growth of 105.06% [1] - The net profit attributable to shareholders was 743 million yuan, reflecting a year-on-year increase of 54.61% [1] - Basic earnings per share for Q3 stood at 0.17 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 6.789 billion yuan, marking a year-on-year growth of 66.73% [1] - The net profit attributable to shareholders for the same period was 1.892 billion yuan, which is a year-on-year increase of 49.57% [1] - Basic earnings per share for the first three quarters were reported at 0.42 yuan [1]

证券代码：601878 证券简称：浙商证券 公告编号：2025-064 浙商证券股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本次会计政策变更的概述 财政部于 2025 年 7 月 8 日发布了标准仓单交易相关会计处理实施问答（以 下简称"标准仓单实施问答"），根据上述要求，公司对会计政策作相应变更，并 按相关要求进行会计处理及信息披露。 公司于 2025 年 10 月 30 日召开第四届董事会第三十七次会议，审议通过《关 于公司会计政策变更的议案》，本次会计政策变更无需提交公司股东会审议。 二、本次会计政策变更的具体情况及对公司的影响 （三）变更后的会计政策 本次会计政策变更后，公司将按照财政部上述标准仓单实施问答的相关规定 执行，变更后的会计政策亦符合《业务管理规则》就大宗商品风险管理业务收入 所作的财务规范。其余未变更部分仍按照财政部前期颁布的《企业会计准则—基 本准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告 以及其他相关规定执行。 ...

Core Insights - Zhejiang Securities reported a significant increase in revenue and net profit for Q3 2025, with revenue reaching 2.97 billion yuan, a year-on-year growth of 105.06% [1] - The net profit attributable to shareholders for Q3 2025 was 743 million yuan, reflecting a year-on-year increase of 54.61% [1] - For the first three quarters of 2025, the company achieved a total revenue of 6.789 billion yuan, up 66.73% compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 1.892 billion yuan, marking a year-on-year growth of 49.57% [1] - Basic earnings per share for Q3 2025 were 0.17 yuan, while for the first three quarters, it was 0.42 yuan [1]

Core Viewpoint - Zhejiang Securities (601878.SH) reported significant growth in its Q3 2025 financial results, driven by increased revenue from brokerage and proprietary trading businesses [1] Financial Performance - Q3 revenue reached 2.97 billion, marking a year-on-year increase of 105.06% [1] - Q3 net profit was 743 million, reflecting a year-on-year growth of 54.61% [1] - For the first three quarters, total revenue amounted to 6.79 billion, up 66.73% year-on-year [1] - Net profit for the first three quarters was 1.89 billion, showing a year-on-year increase of 49.57% [1] Business Drivers - The growth in performance is primarily attributed to the increase in income from securities brokerage and proprietary trading activities [1]

Financial Performance - Total operating revenue for Q3 2025 was CNY 2,969,513,934.48, a decrease of 105.06% compared to CNY 3,896,147,660.09 in the same period last year[3] - Total profit for the period reached CNY 1,155,436,715.94, representing a 90.69% increase from CNY 605,929,843.48 year-on-year[3] - Net profit attributable to shareholders was CNY 743,036,825.55, up 54.61% from CNY 480,581,463.98 in the previous year[3] - Operating revenue for the current reporting period increased by 105.06%, primarily due to growth in securities brokerage and proprietary trading income[12] - Total profit for the current reporting period rose by 90.69%[13] - Net profit attributable to shareholders for the current period increased by 54.61%[13] - Net profit for the first three quarters of 2025 was ¥2,230,018,516.44, up from ¥1,309,056,282.95 in 2024, representing a growth of about 70.3%[26] Assets and Liabilities - The total assets of the company reached CNY 219,048,444,117.21, reflecting a growth of 42.16% from CNY 154,085,739,578.88 at the end of the previous year[8] - Total liabilities increased to ¥172,054,072,013.57 from ¥117,561,353,377.24, reflecting a rise of about 46.3%[23] - The company's equity attributable to shareholders reached ¥36,551,732,763.29, compared to ¥35,192,805,032.13 in the previous year, showing a slight increase of approximately 3.9%[23] Cash Flow - The company reported a net cash flow from operating activities of CNY 5,449,125,706.33, a decrease of 31.80% compared to CNY 7,989,488,599.66 in the previous year[4] - Net cash flow from operating activities decreased by 31.80%, mainly due to an increase in the scale of funds lent out[13] - Net cash flow from investing activities was ¥7,059,513,504.89, significantly improved compared to a negative cash flow of ¥1,944,671,757.23 in the previous period, primarily due to the consolidation of Guodu Securities[16] - Net cash flow from financing activities increased to ¥11,553,105,945.19, compared to a negative cash flow of ¥1,241,676,199.85 in the previous period, mainly due to cash received from bond issuance[16] - The total cash and cash equivalents at the end of the period amounted to CNY 69,737,561,283.88, up from CNY 41,942,613,792.83 in the previous year[31] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 157,460[18] - Zhejiang Shangsan Expressway Co., Ltd. holds 46.46% of the shares, totaling 2,124,825,159 shares[18] - The company reported a significant increase in minority shareholders' profit and loss to ¥338,014,105.26, up 666.08% due to the inclusion of Guodu Securities in the consolidation scope[16] Income and Expenses - The income tax expense increased by 88.84% to ¥478,898,321.62, mainly due to an increase in taxable income for the period[16] - Total operating expenses for the first three quarters of 2025 were ¥4,096,200,181.31, compared to ¥2,508,510,648.13 in 2024, reflecting an increase of approximately 63.3%[26] Earnings and Ratios - Basic earnings per share increased to CNY 0.17, a rise of 30.77% compared to CNY 0.13 in the same period last year[4] - Basic earnings per share for the current period were CNY 0.42, an increase from CNY 0.33 in the previous period[27] - The net asset to liability ratio was 41.69%, down from 48.61% at the end of the previous year[8] - The liquidity coverage ratio improved to 327.00% from 306.34% year-on-year, indicating better short-term financial stability[8] - The risk coverage ratio improved to 337.18% from 298.88% year-on-year, indicating enhanced risk management capabilities[8] Investment and Income Sources - Cash and cash equivalents increased by 46.48% to ¥61.32 billion, driven by an increase in client funds[14] - Margin loans increased by 59.09% to ¥38.54 billion, reflecting an expansion in financing scale[14] - Net interest income for the year-to-date increased by 41.80% to ¥906.11 million, due to higher interest income from financing activities[15] - Investment income surged by 608.91% to ¥2.44 billion, primarily from increased returns on financial instrument investments[15] - Net commission and fee income rose to ¥3,181,679,164.35, up from ¥2,303,184,804.70, marking an increase of approximately 38.1%[25]

Core Viewpoint - Yiling Pharmaceutical achieved a net profit attributable to shareholders of 1 billion yuan in the first three quarters, representing a year-on-year increase of 80.33%, with Q3 net profit reaching 332 million yuan, significantly up year-on-year, slightly exceeding expectations [1] Financial Performance - The company has shown a good recovery in operating performance for the first three quarters of 2025, with expectations for steady growth throughout the year [1] - The gross profit margin is expected to continue to improve due to the decline in traditional Chinese medicine prices, the recovery of gross margins for respiratory products, and ongoing quality enhancement efforts [1] Future Outlook - The company anticipates that net profit growth will continue to outpace revenue growth, supported by the restoration of channel inventory to normal levels and profit margin recovery [1] - The unique patent drug development guided by the theory of collateral diseases and the academic marketing promotion model are expected to contribute positively to future performance [1] - A target price-to-earnings ratio of 23x is set for 2026, with an upgraded rating to "Buy" [1]

Core Viewpoint - Yiling Pharmaceutical achieved a net profit attributable to shareholders of 1 billion yuan in the first three quarters, representing a year-on-year increase of 80.33%, with Q3 net profit reaching 332 million yuan, significantly higher than expected [1] Financial Performance - The company experienced a strong recovery in operating performance in the first three quarters of 2025, indicating a positive outlook for steady growth throughout the year [1] - The expected continuous improvement in gross margin is driven by the decline in traditional Chinese medicine prices and the recovery of gross margins for respiratory products [1] Future Outlook - For 2026, the company is projected to maintain a net profit growth rate that exceeds revenue growth, supported by the recovery of channel inventory to normal levels and profit margin restoration [1] - The unique patent drug development guided by the theory of collateral diseases and the academic marketing promotion model are expected to contribute positively to future performance [1] - The company has been upgraded to a "buy" rating with a target price of 23x PE for 2026 [1]